Background. The pathogenesis of pituitary adenoma (PA) is complex and poorly understood. It is thought that PA has a multifactorial aetiology; genetic factors also have an impact on PA development. Since MMP1 and FGFR4 genes play an important role in tumour growth, differentiation and progression, we decided to determine if the frequency of the genotypes of MMP-1 and FGFR4-R388 polymorphisms influence the development of PA.
INTRODUCTION
Pituitary adenomas (PAs) are usually non-malignant monoclonal tumours with an overall prevalence of 16 .7% (14.4% in autopsy studies and 22.5% in imaging studies) in the general population (1) . The majority of PAs, however, are small and nonfunctional tumours, and only 0.16-0.2% of them are macroadenomas ≥10 mm in diameter (1, 2) . The diagnosis of PAs has improved when MRI scans and hormone analysis in blood serum became more accessible (aggressive biomarkers). The accession of PAs is explained by better detection of microadenomas and the occurring symptoms of macroadenomas (3) . Clinically, PAs are assorted to nonfunctional pituitary adenomas (NFPA) and functional pituitary adenomas (FPA) (4) . Compared to FPA, NFPA are more aggressive and complicated to detect because of lack of symptoms that appear only when adenomas enlarge and start to compress surrounding structures (5) . One of the most important behaviours of PA is invasiveness, which manifests itself by destroying surrounding structures thus triggering a lot of complications (6) . Also, it has been demonstrated that invasiveness could be a sign of poor prognosis (6) .
The pathogenesis of PA is complex and poorly understood. It is thought that PA has a multifactorial aetiology; also, genetic factors have an impact on PA development. MMPs have an important role in tumour progression due to the breakdown of their collagen, which is a fundamental structure within the extracellular matrix (7) (8) (9) . Degradation of the extracellular matrix gradually increases depending on the level of MMP-1 (10) . The matrix metalloproteinase-1 enzyme is important in replacement of collagen fibres in the intercellular matrix (11) . Rutter et al. (12) have announced that the insertion of a G nucleotide at -1607 bp in the nucleotide sequence of the MMP-1 gene promoter generates a new 5′-GGA-3′ sequence that matches the core recognition sequence of the binding site for members of the Ets family of transcription factors (11, 13) . MMP-1 levels increased approximately twice compared to normal concentration when this insertion was present, this allowed MMP-1 to relieve tumour invasion and metastasis (14) . MMP-1 is also thought to be significant to tumour development (11) . Altaş et al. researched the influence of 2G polymorphism on pituitary adenomas and found that 90% of invasive pituitary adenomas manifest in patients who are homozygous for this MMP-1 SNP (11) .
The FGFR4-R388G SNP is associated with MMP expression (13) . Fibroblast growth factors (FGFs) and their receptors (FGFRs) are a family of ligands and receptors that regulate development, growth, differentiation, migration, and angiogenesis (1). It is thought that basic FGF (bFGF; FGF2) is found in bovine pituitary folliculostellate cells responsible for secretion of pituitary hormones (15) . Deletion of FGF10 or its receptor can be accountable for the disruption of initial pituitary development (16) . Ezzat et al. (17) demonstrated that the amount of FGF mRNA in blood serum correlates with aggressiveness of pituitary tumours.
The aim of our study was to determine if the frequency of the genotypes of MMP-1 and FGFR4-R388 had an influence on the development of non-invasive and invasive hypophyseal adenoma.
MATERIALS AND METHODS
Permission (No. P2-9/2003) to undertake the study was obtained from Kaunas Regional Biomedical Research Ethics Committee. The study was conducted in the departments of ophthalmology and neurosurgery of the Hospital of the Lithuanian University of Health Sciences.
Study participants comprised of 100 subjects with the diagnosis of pituitary adenoma, and the control group involved 200 subjects.
The control group was formed by taking into consideration the distribution of age and gender in the pituitary adenoma group. Therefore, the medians of the patients' age of the control group and the pituitary group did not differ statistically significantly (p < 0.05).
The demographic data of the study subjects are presented in Table 1 .
The inclusion criteria of the PA group were as follows: 1) established and confirmed PA via MRI; 2) patient's general good condition; 3) patient's consent to take part in the study; 4) age ≥18 years, 5) no other brain or other localized tumours.
Invasiveness evaluation
All pituitary adenomas were analysed based on MRI findings. The suprasellar extension and sphenoid sinus invasion by PAs were classified according to the Wilson Hardy classification (the Hardy classifi-cation, modified by Wilson) (18) . The degree of suprasellar and parasellar extension was graded as stages A-E. The degree of sellar floor erosion was graded as grades I-IV. Grade III, localized sellar destruction, and grade IV, diffused destruction, were considered invasive PA. The Knosp classification system was used to quantify the invasion of the cavernous sinus, in which only grades III and IV define true invasion of the tumour into the cavernous sinus. Grade 0, no cavernous sinus involvement; grades I and II, the tumour pushes into the medial wall of the cavernous sinus, but does not go beyond the hypothetical line extending between the centres of the two segments of the internal carotid artery (grade I) or it goes beyond such a line, but without passing a line tangent to the lateral margins of the artery itself (grade II); grade III, the tumour extends laterally to the internal carotid artery within the cavernous sinus; grade 4, total encasement of the intracavernous carotid artery (19) . So, grade III and IV tumours were considered to be invasive.
Activeness and recurrence evaluation
The analysis of all pituitary adenomas was based on histopathological findings of PA and hormone levels in blood serum before surgery. All 100 subjects were categorized into two groups -active or inactive PA. The active PA group was not broken down into smaller groups by the increase of specific hormone because dominant tumours were prolactinomas and others would not fill the optimal space in our study. Since some of the 100 subjects had already had surgery in recent years, we categorized them by the recurrence of pituitary adenoma into two groups -with PA and without recurrence.
DNA extraction and genotyping
The DNA extraction and analysis of the gene polymorphism of MMP-1 Rs1799750 and FGFR4-R388 Rs351855 were carried out at the Laboratory of Ophthalmology at the Institute of Neuroscience of the Lithuanian University of Health Sciences. DNA was extracted from 200 μL venous blood (white blood cells) using a DNA purification kit based on the magnetic beads method (Mag-JET Genomic DNA Kit, Thermo Scientific) or the silica-based membrane technology utilizing a genomic DNA extraction kit (GeneJET Genomic DNA Purification Kit, Thermo Scientific), according to the manufacturer's recommendations.
The genotyping of MMP-1Rs1799750 and FGFR4-R388 Rs351855 was carried out using the real-time PCR method. Both single-nucleotide polymorphisms were determined using TaqMan ® Drug Metabolism assays (Thermo Scientific).
The genotyping was performed by a Rotor -Gene Q real-time PCR quantification system (Qiagen, USA), using 2X TaqMan ® Universal Master Mix, TaqMan ® Drug Metabolism assay, and nuclease-free water. Appropriate real-time PCR mixtures of MMP-1Rs1799750 and FGFR4-R388 Rs351855 were prepared for determining single-nucleotide polymorphisms.
A PCR reaction mixture (9 μL) was poured into each of the 72 wells of the Rotor-Disc, and then 1 μL of matrix DNA of the samples (~10 ng) and 1 μL of negative control (-K) were added.
The Allelic Discrimination program was used during the real-time PCR. Then, the assay was continued following the manual provided by the manufacturer (www.qiagen.com, Allelic Discrimination). After that, the Allelic Discrimination program was completed, and the genotyping results were received. The program determined the individual genotypes according to the fluorescence intensity rate of different detectors (VIC and FAM).
Statistical analysis
Statistical analysis was performed using the SPSS/W 20.0 software (Statistical Package for the Social Sciences for Windows). The data are present ed as absolute numbers with percentages Table 2 . Hardy-Weinberg analysis was performed to compare the observed and expected frequencies of Rs1799750 and Rs351855 using the χ 2 test in all groups. The distributions of the Rs1799750 and Rs351855 SNPs in the PA and control groups were compared using the χ 2 test or the Fisher exact test. Binomial logistic regression analysis was performed to estimate the impact of genotypes on PA development. Odds ratios and 95% confidence intervals are presented. The selection of the best genetic model was based on the Akaike Information Criterion (AIC); therefore, the best genetic models were those with the lowest AIC values. Differences were considered statistically significant when p < 0.05.
RESULTS
The frequency of polymorphisms in the MMP-1 gene (c.-1607 2G) Rs1799750 and FGFR4-R388 gene (G>A) Rs351855 was evaluated in both the PA and reference groups ( Table 2 ). The distribution of the analyzed MMP-1 genotypes and allele frequencies in patients with PA did not match and in the control group matched the Hardy-Weinberg equilibrium (p > 0.05). MMP-1 gene polymorphism analysis in the overall group did not reveal any differences in the genotypes distribution between patients with PA and control group subjects ( Table 2 ). The distribution of the analyzed FGFR4-R388 genotypes and allele frequencies in the control group and in the PA group matched the Hardy-Weinberg equilibrium (p > 0.05). FGFR4-R388 gene polymorphism analysis in the overall group did not reveal any differences in the genotype distribution between the patients with PA and the control group subjects ( Table 2) .
Binomial logistic regression analysis in the patients with PA and in the control group was performed (Table 3 ). This analysis revealed that there were no statistically significant variables in the models of the patients with PA and in the control group.
The frequency of the MMP-1 and FGFR4 genotypes in the patients with PA and in the control group Table 5 .
The frequency of the MMP-1 and FGFR4 genotypes in the patients with PA and in the control group by invasiveness of PA was analyzed. Patients with invasive PA had the 1G/2G genotype more frequently than the subjects in the control group: 28.6% vs. 16.5%, p = 0.044. However, the 1G/2G genotype was less frequent in the non-invasive PA group than in the control group: 47% vs. 27%, p = 0.03. The non-invasive PA group did not match the Hardy-Weinberg equilibrium (HWE) for the MMP-1 gene polymorphism (p = 0.02), although the invasive PA and the control group matched HWE for both polymorphisms (P > 0.05). The data are presented in Table 6 . Binomial logistic regression analysis in the invasive PA group for the MMP-1 gene polymorphism revealed that the dominant variable (p = 0.037) was statistically significant. There was no statistical significance in the FGFR4 polymorphism in both groups by the invasiveness of PA (p > 0.05). The data are presented in Table 7 .
We analyzed the frequency of the MMP-1 and FGFR4 genotypes in the patients with PA and in the control group by the activity of PA. The 1G/1G genotype was more frequent in the active PA group than in the control group: 28.4% vs. 16.5%, p = 0.049. The active PA group did not match the Hardy-Weinberg equilibrium for polymorphism in the MMP-1 gene (p = 0.04), although all other groups matched the HWE by genotype distributions (p > 0.05). The data are presented in Table 8 . Binomial logistic regression analysis in the active PA group for MMP-1 revealed that the codominant (p = 0.035) and dominant (p = 0.036) variables were statistically significant, but in the inactive PA group no statistical significance (p > 0.05) was found. There was no statistical significance in the FGFR4 polymorphism in both groups by the activity of PA (p > 0.05) as well. The data are presented in Table 9 .
The frequency of the MMP-1 and FGFR4 genotypes in the patients with PA and in the control group by the recurrence of PA were investigated. The 1G/1G genotype was more frequent in the PA without recurrence group than in the control group: 27.7% vs. 16.5%, p = 0.034. The PA without recurrence group did not match the HWE (p = 0.013), although the PA group with recurrence and control groups matched (p > 0.05). All groups matched the HWE for genotype distributions of FGFR4 (p > 0.05) (Table 10) .
Binomial logistic regression analysis in PA without recurrence group for MMP-1 revealed that the recessive (p = 0.033) variable was statistically The data are presented in Table 11 .
DISCUSSION
Our results revealed that the MMP-1 gene 1G/1G genotype was more frequent in the invasive PA (20) .
Other researchers state that MMP-1 expression is associated with a poor outcome in such cancers as oral carcinoma (21, 22) , nasopharyngeal carcinoma (23), colorectal cancer (CRC) (24) , gastric cancer (25) , and pancreatic cancer (26) ; the relevance of MMP-1 in both CRC and esophageal cancer has been reported by Murray et al. (27, 28) . Also, a few studies have shown that an elevated expression of MMP-1 can promote local growth and formation of brain metastases by breast cancer cells (29, 30) . Other studies have revealed that SLFN5 (human schlafen 5) increases MMP-1 and MMP-13 which promote malignant cell motility in renal cell carcinoma (31) , although in meningiomas MMP-1 did not have an effect on initiation, growth, or progression (32). Monsalves et al. state that the high FGFR4 levels of PAs seem to be responsible for the induction of MMP-1 expression in PAs. A similar correlation has been observed with the FGFR4 expression levels and MMP-1 score of pituitary tumour groups (20) .
It was discovered that the other gene investigated in our study, FGFR4-R388, did not play any predominant role in PA development. It is thought that ptd-FGFR4 expression can provoke invasive growth of pituitary tumour cells in vivo because of deprivation of membranous N-cadherin (1, 33, 34) . The FGF family has been described as having an impact on pituitary tumour activeness, aggressiveness, and invasiveness (11, 13, 15) . A total of 23 FGF ligands have been identified. FGF signals are transduced through FGF receptors with specific affinity for selected receptor isoforms. Although the FGFR4 was found to be an aggressive pituitary tumour marker (35-37), we did not discover any linkage between FGFR SNP and hypophyseal tumour development, invasiveness, and activeness, and we are in disagreement with these studies. Other researchers state that FGFR4-R388 single nucleotide polymorphism is found in up to 50% of the population and has an impact on advanced or treatment-resistant prostate carcinoma, head and neck carcinomas, breast carcinoma, sarcomas, and colorectal carcinoma (38) (39) (40) (41) . At this moment there are an insufficient number of studies in the literature that have investigated the polymorphism of the MMP-1 and FGFR4-G388 genes promoter region in brain tumours, especially in PA. Therefore additional studies should address the progression and invasiveness of PA. The effect of the MMP-1 and FGFR4-G388 promoter polymorphisms will become clearer through these types of studies and such studies will help us understand the relationship between polymorphisms of these genes and progression and invasiveness of the PA tumour.
CONCLUSIONS
The Rs1799750 polymorphism 1G/1G in the MMP-1 gene may play a role in invasive and active PA development. This discovery contradicts with the study by Altaş M. et al. who did not find the same association as we did. It is important to research the effect of MMP-1 in brain tumours to find out the link between this polymorphism and the progression, recurrence, activeness, and invasiveness of PA.
